Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Observational

Inari VISION Registry

NCT06600542 · tracked via the Priya Life Science Italy tracker
Phase
Observational
Started
2025-03-07
Last updated
2026-08-11

Condition(s) studied

Pulmonary Embolism

Investigational drug(s) / intervention(s)

Inari Medical Commercially Available Devices

Inari Medical Commercially Available Devices: Commercially approved Inari Medical devices

Study summary

This registry is a global prospective, non-randomized, multicenter, observational, active post-market data collection of Inari Medical devices and products.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: 1. Willing and able to provide informed consent per institution and geographical requirements 2. Has received treatment with an eligible Inari Medical device. NOTE: If patients are consented prior to their procedure and the procedure does not take place, the patient will be considered a screen failure. 3. Currently within enrollment window relative to their procedure 4. Age ≥ 18 years Exclusion Criteria: 1. Is or will be inaccessible for registry follow-up 2. Meets exclusion criteria required by local requirements 3. Current or planned participation in another drug or device study that, in the investigator's opinion, would interfere with participation in this registry 4. Is pregnant or breastfeeding at the time of enrollment

Primary outcome measure(s)

  • Incidence of device-related, procedure-related, or fatal Adverse Events — Up to 180 days

Trial sites (10)

FacilityCityRegionStatus
Azienda Ospedaliero Universitaria delle Marche Ancona Italy Recruiting
Santa Marta Hospital Lisbon Portugal Recruiting
Southmead Hospital Bristol Bristol United Kingdom Recruiting
Queen Elizabeth University Hospital Glasgow United Kingdom Recruiting
Northwick Park Hospital London United Kingdom Recruiting
Royal Free Hospital London United Kingdom Recruiting
Royal London London United Kingdom Recruiting
UCLH University College London Hospital London United Kingdom Recruiting
Royal Victoria Infirmary Newcastle United Kingdom Recruiting
Great Western Hospital Swindon United Kingdom Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06600542 on ClinicalTrials.gov ↗ ← All trials in Italy